158 related articles for article (PubMed ID: 35596202)
1. Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy.
Hertrampf S; Klotsche J; Schefer Q; Glimm AM; Burmester GR; Hoff P; Schmittat G; Häupl T; Hermann S; Backhaus M; Ohrndorf S
Arthritis Res Ther; 2022 May; 24(1):117. PubMed ID: 35596202
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period.
Glimm AM; Sprenger LI; Haugen IK; Mansmann U; Hermann S; Häupl T; Hoff P; Burmester GR; Backhaus M; Le L; Ohrndorf S
Arthritis Res Ther; 2019 Sep; 21(1):209. PubMed ID: 31533820
[TBL] [Abstract][Full Text] [Related]
3. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
4. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
8. Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Iwata S; Hanami K; Fukuyo S; Miyagawa I; Yamaguchi A; Kawabe A; Saito K; Tanaka Y
Arthritis Res Ther; 2021 Jun; 23(1):154. PubMed ID: 34074349
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
Burmester G; Nüsslein H; von Hinüber U; Detert J; Richter C; Kumke T; Leunikava I; Lendl U; Fricke D; Müller-Ladner U
Clin Exp Rheumatol; 2019; 37(5):842-851. PubMed ID: 30873942
[TBL] [Abstract][Full Text] [Related]
15. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
Blanco FJ; Rubio-Romero E; Sanmartí R; Díaz-Torné C; Talavera P; Dunkel J; Naredo E;
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):345-352. PubMed ID: 30236749
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
19. A multicentre observational study comparing patient reported outcomes to assess reliability of swollen and tender joint assessments and response to certolizumab treatment as compared to clinician assessments in rheumatoid arthritis.
Inderjeeth CA; Inderjeeth AJ; Raymond WD
Int J Rheum Dis; 2019 Jan; 22(1):73-80. PubMed ID: 30187688
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
